Trial · NCT01750086
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT01750086, Phase 4, Completed, Massachusetts General Hospital; results first posted 2016-12-01
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption. Trials, record NCT01750086. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01750086
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
- NCT number
- NCT01750086
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 27 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Teriparatide 40-mcg subcutaneous injection, Denosumab Injection, Alendronate Oral Tablet
- First posted
- 2012-12-17
- Last updated
- 2017-03-27
- Results first posted
- 2016-12-01
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Bone Turnover Marker (Blood Sample) | 8 weeks | The primary outcome was the between-group difference in the teriparatide-induced change in serum c-telopeptide from baseline to week 8. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Bone Turnover Marker (Blood Sample) | 8 weeks | percentage of change in CTX | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Bone Turnover Marker (Blood Sample) | Denosumab 60mg Subcutaneous Injection | -7 | Standard Deviation 11 | percentage of change in CTX | |
| Bone Turnover Marker (Blood Sample) | Alendronate 70mg Weekly x 8 Weeks | 43 | Standard Deviation 29 | percentage of change in CTX |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Denosumab 60mg Subcutaneous Injection | 13 | |
| Overall Study | STARTED | Alendronate 70mg Weekly x 8 Weeks | 14 | |
| Overall Study | COMPLETED | Denosumab 60mg Subcutaneous Injection | 12 | |
| Overall Study | COMPLETED | Alendronate 70mg Weekly x 8 Weeks | 13 | |
| Overall Study | NOT COMPLETED | Denosumab 60mg Subcutaneous Injection | 1 | |
| Overall Study | NOT COMPLETED | Alendronate 70mg Weekly x 8 Weeks | 1 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Lightheadedness | Endocrine disorders | Denosumab 60mg Subcutaneous Injection | 1 | 12 | |
| serious | Lightheadedness | Endocrine disorders | Alendronate 70mg Weekly x 8 Weeks | 0 | 13 | |
| serious | Syncope | Endocrine disorders | Denosumab 60mg Subcutaneous Injection | 0 | 12 | |
| serious | Syncope | Endocrine disorders | Alendronate 70mg Weekly x 8 Weeks | 1 | 13 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Denosumab 60mg Subcutaneous Injection | ||
| Total, all-cause mortality | Alendronate 70mg Weekly x 8 Weeks | ||
| Total, other adverse events | Denosumab 60mg Subcutaneous Injection | 0 | 12 |
| Total, other adverse events | Alendronate 70mg Weekly x 8 Weeks | 0 | 13 |
| Total, serious adverse events | Denosumab 60mg Subcutaneous Injection | 1 | 12 |
| Total, serious adverse events | Alendronate 70mg Weekly x 8 Weeks | 1 | 13 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Denosumab 60mg Subcutaneous Injection vs Alendronate 70mg Weekly x 8 Weeks: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01750086
GET https://conductscience.org/api/trials/v1/NCT01750086/registered